Larimar Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $447.7M
- Price
- $4.32
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.62%
- Volume
- 882.7K
About
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Quick stats
Shares outstanding103.9M
Computed float61.7M
Float / shares59.4%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001374690
Websitehttps://www.larimartx.com
AI Summary
AI-generated1/15
majorbullishearnings
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update
Larimar reported a Q2 net loss of $32.8 million, or $0.30 per share, while holding $156.3 million in cash and equivalents to fund operations into the third quarter of 2027.
The company initiated a rolling BLA submission for nomlabofusp following a successful Type B FDA meeting, with full submission expected in the second half of 2026.
Open-label study data showed sustained increases in skin frataxin levels and clinical improvements, with dosing of the first patient in the confirmatory Phase 3 study expected in Q3 2026.